27318273|t|Design, synthesis and evaluation of novel dual monoamine-cholinesterase inhibitors as potential treatment for Alzheimer's disease.
27318273|a|Current novel therapeutic approach suggests that multifunctional compounds with diverse biological properties and a single bioavailability and pharmacokinetic metabolism, will produce higher significant advantages in treatment of neurodegenerative diseases, such as Alzheimer's disease (AD). Based on this rational, a new class of cholinesterase (ChE)-monoamine oxidase (MAO) inhibitors were designed and synthesized by amalgamating the propargyl moiety of the irreversible selective MAO-B inhibitor, neuroprotective/neurorestorative anti-Parkinsonian drug, rasagiline, into the "N-methyl" position of the ChE inhibitor, anti-AD drug rivastigmine. Initially, we examined the MAO and ChE inhibitory effect of these novel compounds, MT series in vitro and in vivo. Among MT series, MT-031 exhibited higher potency as a dual MAO-A and ChE inhibitor compared to other compounds in acute-treated mice. Additionally, MT-031 was found to increase the striatal levels of dopamine (DA), serotonin (5-HT) and norepinephrine (NE), and prevent the metabolism of DA and 5-HT. Finally, we have demonstrated that MT-031 exerted neuroprotective effect against H2O2-induced neurotoxicity and reactive oxygen species generation in human neuroblastoma SH-SY5Y cells. These findings provide evidence that MT-031 is a potent brain permeable novel multifunctional, neuroprotective and MAO-A/ChE inhibitor, preserves in one molecule entity some of the beneficial properties of its parent drugs, rasagiline and rivastigmine, and thus may be indicated as novel therapeutic approach for AD.
27318273	47	56	monoamine	Chemical	-
27318273	57	71	cholinesterase	Gene	12038
27318273	110	129	Alzheimer's disease	Disease	MESH:D000544
27318273	361	387	neurodegenerative diseases	Disease	MESH:D019636
27318273	397	416	Alzheimer's disease	Disease	MESH:D000544
27318273	418	420	AD	Disease	MESH:D000544
27318273	462	476	cholinesterase	Gene	12038
27318273	478	481	ChE	Gene	12038
27318273	615	620	MAO-B	Gene	109731
27318273	670	682	Parkinsonian	Disease	MESH:D010300
27318273	689	699	rasagiline	Chemical	MESH:C031967
27318273	737	740	ChE	Gene	12038
27318273	757	759	AD	Disease	MESH:D000544
27318273	765	777	rivastigmine	Chemical	MESH:D000068836
27318273	814	817	ChE	Gene	12038
27318273	911	917	MT-031	Chemical	-
27318273	953	958	MAO-A	Gene	17161
27318273	963	966	ChE	Gene	12038
27318273	1022	1026	mice	Species	10090
27318273	1042	1048	MT-031	Chemical	-
27318273	1094	1102	dopamine	Chemical	MESH:D004298
27318273	1104	1106	DA	Chemical	MESH:D004298
27318273	1109	1118	serotonin	Chemical	MESH:D012701
27318273	1120	1124	5-HT	Chemical	MESH:D012701
27318273	1130	1144	norepinephrine	Chemical	MESH:D009638
27318273	1181	1183	DA	Chemical	MESH:D004298
27318273	1188	1192	5-HT	Chemical	MESH:D012701
27318273	1229	1235	MT-031	Chemical	-
27318273	1275	1279	H2O2	Chemical	MESH:D006861
27318273	1288	1301	neurotoxicity	Disease	MESH:D020258
27318273	1306	1329	reactive oxygen species	Chemical	MESH:D017382
27318273	1344	1349	human	Species	9606
27318273	1350	1363	neuroblastoma	Disease	MESH:D009447
27318273	1364	1371	SH-SY5Y	CellLine	CVCL:0019
27318273	1416	1422	MT-031	Chemical	-
27318273	1494	1499	MAO-A	Gene	4128
27318273	1500	1503	ChE	Gene	12038
27318273	1603	1613	rasagiline	Chemical	MESH:C031967
27318273	1618	1630	rivastigmine	Chemical	MESH:D000068836
27318273	1692	1694	AD	Disease	MESH:D000544
27318273	Negative_Correlation	MESH:C031967	MESH:D000544
27318273	Association	MESH:D000544	12038
27318273	Association	MESH:D010300	109731
27318273	Positive_Correlation	MESH:D006861	MESH:D020258
27318273	Negative_Correlation	MESH:C031967	109731
27318273	Negative_Correlation	MESH:D000068836	MESH:D000544
27318273	Negative_Correlation	MESH:D000068836	12038
27318273	Negative_Correlation	MESH:C031967	MESH:D010300
27318273	Comparison	MESH:C031967	MESH:D000068836

